The responsiveness of goal attainment scaling using just one goal in controlled clinical trials: an exploratory analysis.

Assessment Dementia Frailty Goal attainment RCT Responsiveness

Journal

Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688

Informations de publication

Date de publication:
12 May 2020
Historique:
received: 18 06 2019
accepted: 13 04 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 14 5 2020
Statut: epublish

Résumé

Goal Attainment Scaling (GAS) is an individualized outcome measure that allows the setting of personalized treatment goals. We compared the responsiveness of GAS when individuals set only one goal instead of the recommended three or more goals. We conducted exploratory analyses on data from two randomized controlled trials: the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) (n = 130); and the Mobile Geriatric Assessment Team (MGAT) (n = 265). Independent t-tests and standardized response means (SRMs) were used to assess responsiveness of one- vs. multiple-goal GAS. In VISTA, clinician-rated multiple-goal GAS detected higher goal attainment in the intervention group (p = 0.01; SRM = 0.48). One-goal GAS, whether rated by patients or by clinicians, did not detect differences in goal attainment between groups (patient: p = 0.56, SRM = 0.10; clinician: p = 0.10, SRM = 0.29). In MGAT, multiple-goal GAS (outcome goals: p < .001, SRM = 1.29; total goals: p < .001, SRM = 1.52) and one-goal GAS (outcome goals: p < .001, SRM = 0.89; total goals: p < .001, SRM = 0.75), detected significantly higher goal attainment in the intervention group. One-goal GAS detected significant change in response to a patient-centred, multi-domain care initiative. As such, in similar contexts, one-goal GAS may be an effective means of optimizing personalization and improving GAS feasibility through reduced administration time. However, it is not yet clear if one-goal GAS is responsive in the context of a pharmacological intervention and further research is recommended.

Sections du résumé

BACKGROUND BACKGROUND
Goal Attainment Scaling (GAS) is an individualized outcome measure that allows the setting of personalized treatment goals. We compared the responsiveness of GAS when individuals set only one goal instead of the recommended three or more goals.
METHODS METHODS
We conducted exploratory analyses on data from two randomized controlled trials: the Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) (n = 130); and the Mobile Geriatric Assessment Team (MGAT) (n = 265). Independent t-tests and standardized response means (SRMs) were used to assess responsiveness of one- vs. multiple-goal GAS.
RESULTS RESULTS
In VISTA, clinician-rated multiple-goal GAS detected higher goal attainment in the intervention group (p = 0.01; SRM = 0.48). One-goal GAS, whether rated by patients or by clinicians, did not detect differences in goal attainment between groups (patient: p = 0.56, SRM = 0.10; clinician: p = 0.10, SRM = 0.29). In MGAT, multiple-goal GAS (outcome goals: p < .001, SRM = 1.29; total goals: p < .001, SRM = 1.52) and one-goal GAS (outcome goals: p < .001, SRM = 0.89; total goals: p < .001, SRM = 0.75), detected significantly higher goal attainment in the intervention group.
CONCLUSION CONCLUSIONS
One-goal GAS detected significant change in response to a patient-centred, multi-domain care initiative. As such, in similar contexts, one-goal GAS may be an effective means of optimizing personalization and improving GAS feasibility through reduced administration time. However, it is not yet clear if one-goal GAS is responsive in the context of a pharmacological intervention and further research is recommended.

Identifiants

pubmed: 32399731
doi: 10.1186/s41687-020-00196-8
pii: 10.1186/s41687-020-00196-8
pmc: PMC7218040
doi:

Types de publication

Journal Article

Langues

eng

Pagination

35

Subventions

Organisme : Mitacs
ID : IT09427

Références

J Frailty Aging. 2017;6(1):37-45
pubmed: 28244557
J Gerontol A Biol Sci Med Sci. 1999 Dec;54(12):M641-7
pubmed: 10647971
Community Ment Health J. 1968 Dec;4(6):443-53
pubmed: 24185570
J Clin Epidemiol. 2003 Aug;56(8):736-43
pubmed: 12954465
J Clin Epidemiol. 1993 Oct;46(10):1113-8
pubmed: 8410096
Qual Life Res. 2017 Mar;26(3):685-693
pubmed: 28000094
Neuroepidemiology. 1996;15(6):330-8
pubmed: 8930946
Haemophilia. 2018 Jul;24(4):e199-e206
pubmed: 29626387
J Am Geriatr Soc. 2000 Sep;48(9):1080-5
pubmed: 10983907
J Rehabil Med. 2009 Jun;41(7):528-35
pubmed: 19543663
J Am Geriatr Soc. 2018 Nov;66(11):2120-2127
pubmed: 30298901
Arch Phys Med Rehabil. 2008 Apr;89(4):652-9
pubmed: 18373995
J Patient Rep Outcomes. 2019 Apr 1;3(1):20
pubmed: 30931491
Med Care. 1990 Jul;28(7):632-42
pubmed: 2366602
N Engl J Med. 2012 Mar 1;366(9):777-9
pubmed: 22375966
Clin Rehabil. 2011 Dec;25(12):1128-39
pubmed: 21795404
CMAJ. 2006 Apr 11;174(8):1099-105
pubmed: 16554498
Clin Pharmacol Ther. 2010 Oct;88(4):446-9
pubmed: 20856240
Gerontologist. 1998 Dec;38(6):735-42
pubmed: 9868853

Auteurs

Lisa McGarrigle (L)

Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Nova Scotia Health Authority, 5955 Veterans' Memorial Lane, Halifax, NS, B3H 2E1, Canada.
DGI Clinical Inc., 1730 Market St, Halifax, NS, B3J 3N9, Canada.
School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL, UK.

Kenneth Rockwood (K)

Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Nova Scotia Health Authority, 5955 Veterans' Memorial Lane, Halifax, NS, B3H 2E1, Canada.
DGI Clinical Inc., 1730 Market St, Halifax, NS, B3J 3N9, Canada.
Centre for Health Care of the Elderly, Nova Scotia Health Authority, 1421-5955 Veterans' Memorial Lane, Halifax, Nova Scotia, B3H 2E9, Canada.

Classifications MeSH